Perspective Therapeutics (CATX) Equity Average (2011 - 2026)

Perspective Therapeutics has disclosed Equity Average across 15 years of filings, most recently posting $277.2 million for Q1 2026.

• Equity Average for Q1 2026 came in at $277.2 million, down 3.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $277.2 million (down 3.62% YoY), and the FY2025 annual result was $248.8 million, up 36.04% from the prior year.
• Equity Average came in at $277.2 million for Q1 2026 at Perspective Therapeutics, up from $224.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $334.7 million in Q3 2024 to a low of $56.2 million in Q4 2022.
• The 5-year median for Equity Average is $152.5 million (2024), against an average of $178.4 million.
• Across the five-year window, Equity Average soared 255.93% in 2024 and slipped 27.44% in 2025, its largest moves.
• Perspective Therapeutics' Equity Average stood at $56.2 million in 2022, then soared by 54.84% to $87.0 million in 2023, then jumped by 255.93% to $309.6 million in 2024, then declined by 27.44% to $224.6 million in 2025, then advanced by 23.42% to $277.2 million in 2026.
• The last three Equity Average figures came in at $277.2 million (Q1 2026), $224.6 million (Q4 2025), and $254.0 million (Q3 2025), per Business Quant data.